Literature DB >> 20824858

Vaginal dilator therapy for women receiving pelvic radiotherapy.

Tracie Miles1, Nick Johnson.   

Abstract

BACKGROUND: Many vaginal dilator therapy guidelines advocate routine vaginal dilation during and after pelvic radiotherapy to prevent stenosis (abnormal narrowing of the vagina). The UK Gynaecological Oncology Nurse Forum recommend dilation "three times weekly for an indefinite time period". The UK patient charity Cancer Backup advises using vaginal dilators from two to eight weeks after the end of radiotherapy treatment. Australian guidelines recommend dilation after brachytherapy "as soon as is comfortably possible" and "certainly within four weeks and to continue for three years or indefinitely if possible". However, dilation is intrusive, uses health resources and can be psychologically distressing. It has also caused rare but very serious damage to the rectum.
OBJECTIVES: To review the benefits and harms of vaginal dilation therapy associated with pelvic radiotherapy for cancer. SEARCH STRATEGY: Searches included the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4), MEDLINE (1950 to 2008), EMBASE (1980 to 2008) and CINAHL (1982 to 2008). SELECTION CRITERIA: Any comparative randomised controlled trials (RCT) or data of any type which compared dilation or penetration of the vagina after pelvic radiotherapy treatment for cancer. DATA COLLECTION AND ANALYSIS: The review authors independently abstracted data and assessed risk of bias. We analysed the mean difference in sexual function scores and the risk ratio for non-compliance at six weeks and three months in single trial analyses. No trials met the inclusion criteria. MAIN
RESULTS: Dilation during or immediately after radiotherapy can, in rare cases, cause damage and there is no persuasive evidence from any study to demonstrate that it prevents stenosis. Data from one RCT showed no improvement in sexual scores in women who were encouraged to practice dilation. Two case series and one comparative study using historical controls suggest that dilation might be associated with a longer vaginal length but these data cannot reasonably be interpreted to show that dilation caused the change in the vagina. AUTHORS'
CONCLUSIONS: Routine dilation during or soon after cancer treatment may be harmful. There is no reliable evidence to show that routine regular vaginal dilation during or after radiotherapy prevents the late effects of radiotherapy or improves quality of life. Gentle vaginal exploration might separate the vaginal walls before they can stick together and some women may benefit from dilation therapy once inflammation has settled but there are no good comparative supporting data.

Entities:  

Mesh:

Year:  2010        PMID: 20824858      PMCID: PMC4171967          DOI: 10.1002/14651858.CD007291.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  34 in total

1.  Risks of rigid dilation for a radiated vaginal cuff: two related rectovaginal fistulas.

Authors:  Mitchel S Hoffman; Katie E Wakeley; Richard J Cardosi
Journal:  Obstet Gynecol       Date:  2003-05       Impact factor: 7.661

Review 2.  Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy.

Authors:  A S Denton; E J Maher
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 3.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

Review 4.  Dilating the vagina to prevent damage from radiotherapy: systematic review of the literature.

Authors:  N Johnson; T P Miles; P Cornes
Journal:  BJOG       Date:  2010-02-16       Impact factor: 6.531

5.  Sexuality in cancer and palliative care 1: Effects of disease and treatment.

Authors:  A Rice
Journal:  Int J Palliat Nurs       Date:  2000-09

6.  National audit of the management and outcome of carcinoma of the cervix treated with radiotherapy in 1993.

Authors:  A S Denton; S J Bond; S Matthews; S M Bentzen; E J Maher
Journal:  Clin Oncol (R Coll Radiol)       Date:  2000       Impact factor: 4.126

Review 7.  Sexual implications of gynecologic cancer treatments.

Authors:  M C Wilmoth; A Spinelli
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  2000 Jul-Aug

8.  Nursing management of patients receiving brachytherapy for gynecologic malignancies.

Authors:  T K Gosselin; J S Waring
Journal:  Clin J Oncol Nurs       Date:  2001 Mar-Apr       Impact factor: 1.027

9.  The impact of radiotherapy for carcinoma of the cervix on sexual function assessed using the LENT SOMA scales.

Authors:  Susan E Davidson; Meriel P Burns; Jacqueline A Routledge; Ric Swindell
Journal:  Radiother Oncol       Date:  2003-09       Impact factor: 6.280

10.  Preventing vaginal stenosis after brachytherapy for gynaecological cancer: an overview of Australian practices.

Authors:  Letitia Lancaster
Journal:  Eur J Oncol Nurs       Date:  2004-03       Impact factor: 2.398

View more
  16 in total

1.  Chore or priority? Barriers and facilitators affecting dilator use after pelvic radiotherapy for gynaecological cancer.

Authors:  Carissa Bonner; Kathryn Nattress; Caroline Anderson; Jonathan Carter; Chris Milross; Shannon Philp; Ilona Juraskova
Journal:  Support Care Cancer       Date:  2011-12-08       Impact factor: 3.603

2.  Survivorship care plans for people with colorectal cancer: do they reflect the research evidence?

Authors:  V D'Souza; H Daudt; A Kazanjian
Journal:  Curr Oncol       Date:  2016-10-25       Impact factor: 3.677

3.  Toward clinical care guidelines for supporting rehabilitative vaginal dilator use with women recovering from cervical cancer.

Authors:  Kimberley Cullen; Karen Fergus; Tracey DasGupta; Iwa Kong; Marg Fitch; Catherine Doyle; Lauran Adams
Journal:  Support Care Cancer       Date:  2013-02-17       Impact factor: 3.603

Review 4.  Vaginal dilator therapy for women receiving pelvic radiotherapy.

Authors:  Tracie Miles; Nick Johnson
Journal:  Cochrane Database Syst Rev       Date:  2014-09-08

5.  Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Crystal S Denlinger; Tara Sanft; K Scott Baker; Shrujal Baxi; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Elizabeth Kvale; Robin M Lally; Terry S Langbaum; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Deborah A Freedman-Cass; Nicole R McMillian
Journal:  J Natl Compr Canc Netw       Date:  2017-09       Impact factor: 11.908

6.  Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis.

Authors:  Vinai Gondi; Søren M Bentzen; Kathryn L Sklenar; Emily F Dunn; Daniel G Petereit; Scott P Tannehill; Margaret Straub; Kristin A Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-14       Impact factor: 7.038

7.  Interventions to address sexual problems in people with cancer.

Authors:  L Barbera; C Zwaal; D Elterman; K McPherson; W Wolfman; A Katz; A Matthew
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

8.  Survivorship: sexual dysfunction (female), version 1.2013.

Authors:  Crystal S Denlinger; Robert W Carlson; Madhuri Are; K Scott Baker; Elizabeth Davis; Stephen B Edge; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Elizabeth Kvale; Terry S Langbaum; Jennifer A Ligibel; Mary S McCabe; Kevin T McVary; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Tracey O'Connor; Electra D Paskett; Muhammad Raza; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole McMillian; Deborah Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2014-02       Impact factor: 11.908

9.  Assessment of treatment-induced female sexual morbidity in oncology: is this a part of routine medical follow-up after radical pelvic radiotherapy?

Authors:  I D White; H Allan; S Faithfull
Journal:  Br J Cancer       Date:  2011-09-06       Impact factor: 7.640

10.  A nurse- and peer-led support program to assist women in gynaecological oncology receiving curative radiotherapy, the PeNTAGOn study (peer and nurse support trial to assist women in gynaecological oncology): study protocol for a randomised controlled trial.

Authors:  Penelope Schofield; Ilona Juraskova; Rebecca Bergin; Karla Gough; Linda Mileshkin; Meinir Krishnasamy; Kate White; David Bernshaw; Sylvia Penberthy; Sanchia Aranda
Journal:  Trials       Date:  2013-02-11       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.